Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-Year follow-up results of the French Adjuvant Study Group 05 randomized trial

Journal of Clinical Oncology

Volumn 23, Issue 12, 2005, Pages 2686-2693

  Bonneterre, Jacques ^a   Roché, Henri ^a   Kerbrat, Pierre ^a   Brémond, Alain ^a   Fumoleau, Pierre ^a   Namer, Moïse ^a   Gaudier, Marie Josèphe ^a   Schraub, Simon ^a   Fargeot, Pierre ^a   Chapelle Marcillac, Isabelle ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN; ANTINEOPLASTIC AGENT; FEC PROTOCOL;

ACUTE TOXICITY; ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; EARLY CANCER; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; FRANCE; HEAD AND NECK CANCER; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HISTIOCYTOMA; HUMAN; LEUKEMIA; LUNG CANCER; LYMPH NODE; LYMPHOMA; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SECOND CANCER; SIDE EFFECT; SINUS TACHYCARDIA; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THYROID CANCER; VOMITING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DOSE RESPONSE; DRUG EFFECT; HEART; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEART; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS;

EID: 21044437811     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.059     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
2. Carlson RW, Anderson BO, Bensinger W, et al: NCCN practice guidelines for breast cancer. Oncology 14:33-49, 2000
3. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
4. The Italian Multicentre Breast Study with Epirubicin: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian Multicentre Trial. J Clin Oncol 6:976-982, 1988
5. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
6. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611, 2001
7. Snedecor GW, Cochran WG: Statistical Methods (ed 7). Ames, IA, Iowa State University Press, 1980
8. Duncan DB: P-tests and intervals for comparison suggested by the data. Biometrics 31: 339-359, 1975
9. Meyer RM, Browman GP, Samosh ML, et al: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386-2393, 1995
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 135:185-198, 1972
12. Cox DR: Regression models and life-tables. J R Stat Soc [B] 34:187-202, 1972
13. Chen Y, Thompson W, Semenciw R, et al: Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8:855-861, 1999
14. Simon H, Monnier A, Namer M, et al: Prognostic factors of contralateral breast cancer in 3,653 early breast cancer patients: 9-year follow-up results of French Adjuvant Study Group trials. Proc Am Soc Clin Oncol 23:14, 2004 (abstr 551)
15. Bonneterre J, Roché H, Kerbrat P, et al: Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 22:3070-3079, 2004
16. National Institutes of Health Consensus Development Panel: Conference Statement: Adjuvant Therapy for Breast Cancer. J Natl Cancer Inst 93:979-989, 2000
17. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: Updated International Expert Consensus of the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003
18. Fumoleau P, Kerbrat P, Romestaing P, et al: Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21:298-305, 2003
19. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
20. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. J Clin Oncol 14:35-45, 1996
21. Mouridsen H, Andersen J, Andersson M, et al: Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 18:68a, 1999 (abstr 254)
22. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide,
23. epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
24. Pritchard KI, Levine MN, Bramwell VHC, et al: A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: Update of NCIC CTG MA. 5. Breast Cancer Res Treat 76:533, 2002 (suppl 1, abstr)
25. Lopez M, Papaldo P, DiLauro L, et al: 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology 46:1-5, 1989
26. Citron ML, Berry DA, Cirrincione CT, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21:1431-1439, 2003
27. Mamounas EP, Bryant J, Lembersky BC, et al: Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol 22:4, 2003 (abstr 12)
28. Fumoleau P, Bonneterre J, Luporsi E: Adjuvant chemotherapy for node-positive breast cancer patients: Which is the reference today? J Clin Oncol 21:1190-1192, 2003
29. Fumoleau P, Roché H, Asselain B, et al: Evaluation of early cardiotoxicity in breast cancer patients treated with epirubicin (E)-based adjuvant chemotherapy: Results from the PACs 01 study. Proc Am Soc Clin Oncol 20:28a, 2001 (abstr 107)
30. Levine MN, Eisen A: Anthracycline adjuvant chemotherapy: How much is enough? J Clin Oncol 19:599-601, 2001
31. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol Classic Papers and Current Comments, Breast Cancer 5:656-657, 2002